Core Viewpoint - Gilead Sciences, Inc. (NASDAQ:GILD) is highlighted as one of the most profitable stocks on NASDAQ, with recent price target increases from Truist Securities and Citigroup indicating strong investor confidence in the company's future performance [1][3]. Group 1: Price Target Adjustments - Truist Securities raised its price target on Gilead Sciences to $145 from $140 while maintaining a Buy rating, citing revisions in estimates for the drug YEZTUGO and updates on upcoming launches [2]. - Citigroup also increased its price target for Gilead Sciences to $156 from $140, maintaining a Buy rating, as part of a broader Q4 preview for biopharmaceutical stocks [3]. Group 2: Company Overview - Gilead Sciences is a biopharmaceutical company focused on developing medicines for life-threatening diseases, including HIV, viral hepatitis, and cancer [4].

Core Viewpoint - Truist has raised the price target for Gilead (GILD) to $145 from $140 while maintaining a Buy rating, reflecting positive sentiment ahead of Q4 earnings in the Biotech sector [1] Group 1: Price Target and Rating - Truist increased Gilead's price target to $145 from $140 [1] - The firm continues to hold a Buy rating on Gilead shares [1] Group 2: Q4 Earnings Preview - The research note is part of a broader preview for Q4 earnings in the Biotech industry [1] - Adjustments to Yeztugo numbers are being made in anticipation of Q4 EPS [1] Group 3: Product Launches and Estimates - Timelines are being tweaked based on updated guidance for near-term product launches, including BIC/LEN in 2H25 and the US launch of Hepcludex [1] - There are expansion opportunities for Livdelzi, and estimates for the anito-cel launch are being fine-tuned following FDA guidance [1]

Group 1 - Gilead Sciences Inc. is considered one of the best stocks for the next decade, with Morgan Stanley raising its price target to $151 from $147 and maintaining an Overweight rating [1] - Regulatory and political uncertainties affecting the biopharma sector are expected to diminish, leading to a renewed focus on the industry's financial and operational performance [1][3] - Gilead announced positive topline results from its Phase 3 ARTISTRY-2 clinical trial, showing that the investigational regimen BIC/LEN is statistically non-inferior to the current standard-of-care, BIKTARVY, for HIV-1 treatment [2][3] Group 2 - The ARTISTRY-2 trial met its primary efficacy endpoint of maintaining HIV-1 RNA levels below 50 copies/mL at Week 48 for adults who switched from BIKTARVY to BIC/LEN [2] - Gilead plans to use the ARTISTRY-2 results along with data from the ARTISTRY-1 trial for upcoming regulatory submissions and aims to present detailed findings at a future scientific congress [3] - These advancements mark a significant step in Gilead's 35-year history of HIV innovation, potentially providing a new treatment option for millions living with HIV globally [3]